Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Short Interest Update

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Free Report) saw a significant decline in short interest during the month of July. As of July 15th, there was short interest totaling 340,264 shares, a decline of 95.7% from the June 30th total of 7,845,889 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average daily trading volume, of 2,998,595 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Robert W. Baird downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. HC Wainwright cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $35.00 to $31.50 in a research report on Thursday, May 28th. Weiss Ratings raised Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, June 3rd. Oppenheimer lowered Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 7th. Finally, Stephens set a $32.00 price target on Catalyst Pharmaceuticals in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, Catalyst Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $32.00.

Get Catalyst Pharmaceuticals alerts:

Check Out Our Latest Analysis on Catalyst Pharmaceuticals

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada raised its holdings in Catalyst Pharmaceuticals by 39.1% during the first quarter. Royal Bank of Canada now owns 213,469 shares of the biopharmaceutical company’s stock worth $5,177,000 after purchasing an additional 60,040 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Catalyst Pharmaceuticals by 5.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 72,052 shares of the biopharmaceutical company’s stock valued at $1,749,000 after purchasing an additional 3,800 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Catalyst Pharmaceuticals by 11.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock valued at $76,035,000 after purchasing an additional 333,100 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Catalyst Pharmaceuticals by 99.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 526,297 shares of the biopharmaceutical company’s stock valued at $12,763,000 after purchasing an additional 262,392 shares during the period. Finally, Intech Investment Management LLC increased its position in shares of Catalyst Pharmaceuticals by 6.5% during the 1st quarter. Intech Investment Management LLC now owns 70,087 shares of the biopharmaceutical company’s stock valued at $1,700,000 after purchasing an additional 4,261 shares during the period. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

Catalyst Pharmaceuticals stock remained flat at $31.49 during trading hours on Friday. Catalyst Pharmaceuticals has a 12-month low of $19.05 and a 12-month high of $32.56. The firm has a market cap of $3.86 billion, a PE ratio of 18.10, a price-to-earnings-growth ratio of 0.96 and a beta of 0.74. The firm has a fifty day simple moving average of $31.39 and a 200 day simple moving average of $27.30.

Catalyst Pharmaceuticals Company Profile

(Get Free Report)

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).

Featured Stories

• Five stocks we like better than Catalyst Pharmaceuticals
• AMD and Cerbras Create A New Blueprint For Hardware
• Intel Earnings Reveal Whether the Chip Selloff Created a Buy
• CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
• Plugging In: How Kinder Morgan Powers Up Profits

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.